Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Cristina Vo

Allergy Danbury, CT Medical Doctor

NPI 1972034460 CMS profile 11323560

107 Newtown Rd Ste 1B, Danbury, CT 06810

Open in the dashboard

General payments

$3,850

172 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cristina Vo of Danbury, CT is reported in the CMS Open Payments database as having received $3,850 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,305 61
2024 General $1,025 43
2023 General $1,412 63
2022 General $108 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cristina Vo
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Cristina Vo were reported at $1,305. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Cristina Vo Allergy median Middle half National median
2019 $0 $506 $151–$1,337 $163
2020 $0 $409 $108–$1,162 $114
2021 $0 $549 $125–$1,485 $132
2022 $108 $666 $161–$1,594 $149
2023 $1,412 $780 $186–$1,916 $160
2024 $1,025 $1,031 $271–$2,196 $164
2025 $1,305 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,110 69 payments
  2. Genzyme Corporation $767 21 payments
  3. AstraZeneca Pharmaceuticals LP $447 16 payments
  4. Regeneron Healthcare Solutions, Inc. $282 12 payments
  5. Genentech USA, Inc. $264 9 payments
  6. Novartis Pharmaceuticals Corporation $218 11 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $164 6 payments
  8. OptiNose US, Inc. $102 5 payments
  9. Amgen Inc. $97 5 payments
  10. Pfizer Inc. $95 4 payments
  11. Other $303 14 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,850 171 payments
  2. Education $1 1 payment
Products named General payments · program years 2022–2025
  1. DUPIXENT Immunology $1,014 30 payments
  2. NUCALA $870 53 payments
  3. TEZSPIRE $352 10 payments
  4. Xolair $264 9 payments
  5. TRELEGY ELLIPTA $240 16 payments
  6. DUPIXENT Inflammation And Immunology $154 7 payments
  7. DUPIXENT Immunology And Inflammation $128 5 payments
  8. AREXVY $106 5 payments
  9. Rhapsido $104 5 payments
  10. Xhance $102 5 payments
  11. Other $956 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

171

Median for Allergy/ Immunology: 449

Drug cost

$48,644

Median for Allergy/ Immunology: $169,700

Branded share of claims

39.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 26 $43,073
Epinephrine Generic 19 $3,063
Albuterol Sulfate Hfa Albuterol Sulfate Brand 28 $878
Azelastine-Fluticasone Azelastine/Fluticasone Brand 13 $584
Montelukast Sodium Generic 56 $555
Fluticasone Propionate Generic 13 $297
Ipratropium Bromide Generic 16 $194

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$19,210

Medicare's payments for the services billed

Medicare patients

60

Average age 72

Services billed

1,314

41 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 43%
Depression 25%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $303
  • Regeneron Healthcare Solutions, Inc. $41
$344 — —
NUCALA
  • GlaxoSmithKline, LLC. $196
$196 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $56
  • Genentech USA, Inc. $30
$86 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $54
$54 — —
AUVI-Q
  • kaleo, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record